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Abstract
Background
Type 2 diabetes mellitus (T2DM) disproportionately affects individuals of nonwhite ethnic
origin. Timely and appropriate initiation and intensification of glucose-lowering therapy is
key to reducing the risk of major vascular outcomes. Given that ethnic inequalities in out-
comes may stem from differences in therapeutic management, the aim of this study was to
identify ethnic differences in the timeliness of initiation and intensification of glucose-lower-
ing therapy in individuals newly diagnosed with T2DM in the United Kingdom.
Methods and findings
An observational cohort study using the Clinical Practice Research Datalink was conducted
using 162,238 adults aged 18 and over diagnosed with T2DM between 1990 and 2017
(mean age 62.7 years, 55.2% male); 93% were of white ethnicity (n = 150,754), 5% were
South Asian (n = 8,139), and 2.1% were black (n = 3,345). Ethnic differences in time to initia-
tion and intensification of diabetes treatment were estimated at three time points (initiation
of noninsulin monotherapy, intensification to noninsulin combination therapy, and intensifi-
cation to insulin therapy) using multivariable Cox proportional hazards regression adjusted
for factors a priori hypothesised to be associated with initiation and intensification: age, sex,
deprivation, glycated haemoglobin (HbA1c), body mass index (BMI), smoking status,
comorbidities, consultations, medications, calendar year, and clustering by practice. Odds
of experiencing therapeutic inertia (failure to intensify treatment within 12 months of HbA1c
>7.5% [58 mmol/mol]), were estimated using multivariable logistic regression adjusted for
the same hypothesised confounders. Noninsulin monotherapy was initiated earlier in South
Asian and black groups (South Asian HR 1.21, 95% CI 1.08–1.36, p < 0.001; black HR 1.29,
95% CI 1.05–1.59, p = 0.017). Correspondingly, no ethnic differences in therapeutic inertia
were evident at initiation. Intensification with noninsulin combination therapy was slower in
both nonwhite ethnic groups relative to white (South Asian HR 0.80, 95% CI 0.74–0.87, p <
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0.001; black HR 0.79, 95% CI 0.70–0.90, p < 0.001); treatment inertia at this stage was
greater in nonwhite groups relative to white (South Asian odds ratio [OR] 1.45, 95% CI
1.23–1.70, p < 0.001; black OR 1.43, 95% CI 1.09–1.87, p = 0.010). Intensification to insulin
therapy was slower again for black groups relative to white groups (South Asian HR 0.49,
95% CI 0.41–0.58, p < 0.001; black HR 0.69, 95% CI 0.53–0.89, p = 0.012); correspond-
ingly, treatment inertia was significantly higher in nonwhite groups at this stage relative to
white groups (South Asian OR 2.68, 95% CI 1.89–3.80 p < 0.001; black OR 1.82, 95% CI
1.13–2.79, p = 0.013). At both stages of treatment intensification, nonwhite groups had
fewer HbA1c measurements than white groups. Limitations included variable quality and
completeness of routinely recorded data and a lack of information on medication
adherence.
Conclusions
In this large UK cohort, we found persuasive evidence that South Asian and black groups
intensified to noninsulin combination therapy and insulin therapy more slowly than white
groups and experienced greater therapeutic inertia following identification of uncontrolled
HbA1c. Reasons for delays are multifactorial and may, in part, be related to poorer long-
term monitoring of risk factors in nonwhite groups. Initiatives to improve timely and appropri-
ate intensification of diabetes treatment are key to reducing disparities in downstream vas-
cular outcomes in these populations.
Author summary
Why was this study done?
• In the UK, ethnic minority populations, particularly of South Asian and black African/
Caribbean descent, have a higher risk of type 2 diabetes mellitus (T2DM) and related
adverse outcomes, such as cardiovascular disease, than the white population.
• Timely and appropriate diabetes treatment can substantially reduce risk of adverse out-
comes associated with T2DM.
• We sought to quantify ethnic differences in time to initiation and intensification of dia-
betes treatment among individuals newly diagnosed with T2DM to assess whether these
clinically modifiable factors may contribute to ethnic differences in outcomes.
What did the researchers do and find?
• We used routinely recorded data from general practices across the UK to identify people
newly diagnosed with T2DM and compared how long it took to initiate and intensify
diabetes treatment, comparing people of white, South Asian, and black ethnicity.
• We found that South Asian and black groups initiated diabetes treatment more quickly
than white groups but were slower to intensify to second- and third-line treatment
regimes.
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What do these findings mean?
• Although time to initial treatment of type 2 diabetes was appropriate, ethnic disparities
in subsequent longer-term treatment may contribute to the worse outcomes seen in eth-
nic minority populations in the UK.
• Interventions to improve timely and appropriate intensification of diabetes treatment
are key to reducing disparities in the downstream adverse outcomes of T2DM.
Introduction
The burden of type 2 diabetes mellitus (T2DM) is growing worldwide, disproportionately
affecting individuals of nonwhite ethnic origin [1–3]. Around 6% of the UK population have
T2DM, with the risk of developing T2DM approximately 2- to 4-fold greater in migrant popu-
lations of South Asian or black African or Caribbean descent. Additionally, once diagnosed
with T2DM, the lifetime risk of developing cardiovascular conditions is higher again in minor-
ity ethnic groups than those of white European origin [4–11].
Timely and appropriate initiation and intensification of glucose-lowering therapy have been
shown to substantively reduce adverse diabetes outcomes [12,13]. In the UK, clinical guidelines
for the therapeutic management of blood glucose recommend that newly diagnosed individuals
initiate with noninsulin monotherapy, usually metformin, if their glycated haemoglobin (HbA1c)
level is above 6.5% (48 mmol/mol). Intensification with additional noninsulin therapies, and ulti-
mately insulin, is recommended if HbA1c remains above 7.5% (58 mmol/mol) [14].
Poor glycaemic control is associated with an increased risk of macrovascular complications
(such as coronary disease and stroke) and microvascular complications (such as diabetic retinopa-
thy, neuropathy, and kidney disease). One key driver of suboptimal glucose management is thera-
peutic inertia, defined as failure to appropriately initiate or intensify treatment in a timely manner
following identification of uncontrolled risk factor levels. In the UK, it has been shown that one-
third of individuals do not achieve target HbA1c levels of 7.5% (58 mmol/mol), despite clinical
guidelines recommending that therapy be intensified within 3–6 months of identifying a raised
HbA1c [14,15]. Furthermore, a 2019 UK study has highlighted the high economic burden associ-
ated with therapeutic inertia, with costs related to increases in diabetes-related complications and
lost workplace productivity equalling £2.6 million over the next 10 years [16].
Given that ethnic inequalities in diabetes care and outcomes can accumulate from even before
diagnosis, it is essential to identify where along the care pathway disparities arise. In particular, it
is essential to identify easily modifiable aspects of the pathway that may contribute to inequalities.
As such, the aim of this study is to identify ethnic differences in the timeliness of initiation and
intensification of glucose-lowering treatment in individuals with newly diagnosed T2DM in the
UK—specifically, (1) ethnic differences in the ordering of glucose-lowering treatments, (2) ethnic
differences in time to initiation and intensification of treatment, and (3) ethnic differences in
treatment delays (therapeutic inertia) following identification of uncontrolled HbA1c.
Methods
Study design and population
An observational cohort study utilising the Clinical Practice Research Datalink (CPRD) was
undertaken. The CPRD is a clinical research database containing anonymised longitudinal
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primary care records for approximately 15 million people from 714 general practices and has
been shown to be representative of the UK population with respect to age, sex, and ethnicity
[17]. Adults aged 18 and over who were registered between January 1990 and December 2017,
with at least 12 months of continuous registration prior to first recorded diagnosis of T2DM,
were included in the study. T2DM was identified using an adjudication algorithm developed
to minimise misclassification of diabetes status and type in electronic health records (EHRs)
[18].
Transitions between treatment stages were analysed in three time periods: (1) time from
diagnosis to initiation of noninsulin monotherapy, (2) time from noninsulin monotherapy to
intensification with noninsulin combination therapy, and (3) time from noninsulin combina-
tion therapy to intensification with insulin therapy.
Covariates
Self-reported ethnicity was identified using Read codes and collapsed into the five main cate-
gories of the 2001 UK census (white, South Asian, black African/Caribbean, mixed, and
other). For individuals with more than one ethnicity code on their primary care record, an
algorithm was used to assign a best ‘single’ ethnicity—based on the most commonly and most
recently recorded codes (S1 Fig) [19]. Age at diagnosis was calculated by subtracting the year
of birth from year of diagnosis and was divided into 10-year age bands. Deprivation was mea-
sured using quintiles of the Index of Multiple Deprivation (IMD) [20].
For the time from diagnosis to initiation with noninsulin monotherapy, baseline was
defined as the date of T2DM diagnosis. Baseline covariates were identified from the value clos-
est to the date of T2DM diagnosis from the 12 months preceding or the 3 months following
diagnosis. These included HbA1c, body mass index (BMI), systolic blood pressure (SBP) and
diastolic blood pressure (DBP), and smoking status (categorised as ‘never smoker’, ‘current
smoker’, and ‘ex-smoker’). Although BMI was considered as a continuous covariate in the ana-
lytical models, descriptive statistics categorised BMI according to the standard categories of
underweight, normal weight, overweight, and obese, with adjustments for South Asian ethnic-
ity as recommended by WHO, which classify normal weight as between 18.5 and 22.9 kg/m2,
overweight as between 23 and 27.4 kg/m2, and obesity as 27.5 kg/m2 or over for this ethnic
group [21].
Comorbidities were considered present at baseline if recorded at any time prior to diagno-
sis. These included depression, macrovascular disease (hypertension, myocardial infarction,
angina, stroke, and heart failure), and microvascular disease (chronic kidney disease, retinopa-
thy, and neuropathy) (see S1 Table for all code lists). The number of consultations and oral
medications in the 6 months prior to diagnosis was also included as baseline covariates.
For the time from noninsulin monotherapy to noninsulin combination therapy, baseline
was defined as the date of initiation of noninsulin therapy. Baseline HbA1c, BMI, and smoking
status were derived from the date closest to the date of monotherapy initiation in the 6 months
preceding. Counts of consultations and oral medications were calculated from the 6 months
prior to monotherapy initiation. Comorbidities were considered present if recorded at any
time prior to monotherapy initiation. For the time from noninsulin combination therapy to
insulin therapy, baseline was defined as the date of initiation of noninsulin combination ther-
apy, with baseline HbA1c, BMI, smoking status, counts of consultations and oral medications,
and comorbidities defined as above.
For each of the three time periods of interest, additional between-treatment variables were
constructed. These included the number of HbA1c measurements and the number of consul-
tations between treatment stages.
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Glucose-lowering treatment
Glucose-lowering treatment was identified from GP prescribing data and categorised into six
classes: metformin, sulfonylurea, newer agents (dipeptidyl peptidase-4 inhibitor [DPP4i],
sodium-glucose cotransporter-2 inhibitor [SGLT2i], and glucagon-like peptide-1 [GLP-1]
receptor agonists), thiazolidinediones, insulin, and other drugs. Newer agents were grouped
together because they represent treatment strategies used for similar stages of diabetes
progression.
Statistical analysis
Patterns of glucose-lowering treatment. Firstly, the proportion of individuals prescribed
each class of glucose-lowering drug was calculated from the initiation of a single drug through
to the addition of up to four more drugs and compared between ethnic groups. Secondly, pat-
terns of treatment up-titration were compared between ethnic groups using sequence analysis.
Sequences included (1) staying on a single drug regime for the entire follow-up period, (2)
moving between two drug regimes, and (3) moving between three drug regimes.
Time to treatment initiation and intensification
Multilevel multivariable proportional hazard models assuming an exponential baseline hazard
function were employed to identify ethnic differences in time to initiation and intensification
of glucose-lowering treatment while accounting for the clustering of individuals within general
practices. Individuals free from glucose-lowering treatment at the date of T2DM diagnosis
were eligible for inclusion. Individuals who initiated diabetes treatment in the 90 days prior to
diagnosis were considered to be ‘baseline initiators’ and, for analytical purposes, had their ini-
tiation date moved to 1 day after diagnosis to allow entry into the cohort. For initiation of non-
insulin monotherapy, follow-up time began at the date of T2DM diagnosis and ended at the
date of initiation. For intensification to noninsulin combination therapy, follow-up time
began at commencement of monotherapy and ended at the date of intensification with combi-
nation therapy. For intensification to insulin therapy, follow-up time began at the commence-
ment of noninsulin combination therapy and ended at the date of intensification with insulin.
For individuals who did not initiate or intensify with the drug of interest during the follow-
up period, follow-up time was censored at the earliest of the following: date of intensifying to a
different drug, death, transferring out of the practice, or last data collection. For example, indi-
viduals who initiated with a treatment other than noninsulin monotherapy were censored at
the date the alternative treatment was commenced, and individuals who intensified directly
from noninsulin monotherapy to insulin were censored at the date of insulin initiation.
All models adjusted for hypothesised covariates as identified in the directed acyclic diagram
(S2 Fig); namely, age at diagnosis, sex, deprivation, year of diabetes diagnosis (to account for
secular trends in prescribing guidelines and treatment availability), HbA1c, BMI, and smoking
status at the start of each follow-up period; presence of depression, micro- and macrovascular
comorbidities at the start of each follow-up period; and count of consultations and oral medi-
cations in the 6 months prior to the start of each follow-up period. Models for intensification
to combination therapy and insulin therapy additionally adjusted for time since diagnosis. As
individuals attending the same general practice may have similar levels of care provision and
clinical coding, multilevel modelling was used to account for the clustering of people within
practices.
Because of overdispersion in the Poisson model, multilevel multivariable negative binomial
regression was used to estimate ethnic differences in the count of HbA1c measurements, and
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consultations between treatment stages adjusted for all hypothesised confounders and cluster-
ing by practice.
Ethnic differences in therapeutic inertia
As there is no single accepted definition of therapeutic inertia, we adopted a definition used in
previous UK database studies [22–24]. For the purposes of our study, therapeutic inertia was
defined as the failure to intensify treatment within 12 months of having an HbA1c of>7.5%
(58 mmol/mol) recorded by the general practitioner. Individuals with any raised HbA1c fol-
lowing (1) diagnosis, (2) initiation of noninsulin monotherapy, or (3) initiation of noninsulin
combination therapy with at least 12 months of follow-up were included in the analysis. Mod-
els to estimate ethnic differences in the odds of experiencing therapeutic inertia were con-
structed adjusting for all hypothesised confounders. Models for treatment inertia around time
of intensification to combination therapy and insulin therapy additionally adjusted for time
between first raised HbA1c and T2DM diagnosis in each of the three time periods. Descriptive
statistics for factors associated with therapeutic inertia including the number of HbA1c’s
above 7.5% (58 mmol/mol) measured between first raised HbA1c and treatment intensifica-
tion, the number of consultations between first raised HbA1c and treatment intensification,
and the proportion of individuals with a consultation within 3 months of the first recorded
raised HbA1c were calculated and presented by ethnic group.
For all analyses, individuals of white ethnicity were considered as the reference population.
Comparisons between the white, South Asian, and black African/Caribbean populations are
reported in the main results. Analyses were conducted as specified in the scientific protocol
(see S1 Text). Due to the fact that routinely recorded data in primary care EHRs are likely to
be missing not at random, multiple imputation of missing data was not considered appropriate
because the assumption of missing at random was unlikely to be met. As such, a complete case
analysis approach was employed [25]. All analyses were completed using Stata version 15 and
reported according to the RECORD guidelines (see S1 RECORD Checklist).
Secondary analysis
Firstly, as current guidelines for diabetes management in the UK suggest a threshold of 6.5%
(48 mmol/mol) for initiation of diabetes treatment, a secondary analysis of ethnic differences
in treatment inertia at initiation of noninsulin monotherapy was conducted using >6.5% at
the definition of raised HbA1c instead of>7.5% (58 mmol/mol). Secondly, as 12 months’ min-
imum follow-up was required for inclusion into the analysis of treatment inertia, the ethnic
breakdown of those included in the analysis was compared to that of those excluded for lack of
12 months’ follow-up at each stage.
Ethical approval
Ethical and scientific approval for this study were granted by the Independent Scientific Advi-
sory Committee (ISAC) (protocol 17_087R) and the London School of Hygiene & Tropical
Medicine (project ID 13409).
Results
From a total of 425,811 adults aged 18 and over who were diagnosed with T2DM between
1990 and 2017, 162,238 individuals of white, South Asian, or black ethnicity with at least 1 year
of continuous registration prior to diagnosis were included in the study (Fig 1). Individuals of
mixed/other ethnicity (n = 2,794) and unknown ethnicity (n = 75,258) were excluded from the
PLOS MEDICINE Ethnic differences in initiation and intensification of T2DM treatment
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Fig 1. Population inclusion flowchart. CPRD, Clinical Practice Research Datalink; T2DM, type 2 diabetes mellitus.
https://doi.org/10.1371/journal.pmed.1003106.g001
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study population (comparisons between the white, other, and unknown ethnic groups are
reported in S2–S4 Tables). Individuals in the study cohort contributed a mean of 6.2 years of
follow-up. The ethnic breakdown of the study cohort was 92.9% white (n = 150,754), 5.0%
South Asian (n = 8,139), and 2.1% black (n = 3,345). Compared with the white group, age at
diagnosis was markedly younger in ethnic minority groups (South Asian, 55 years; black, 56
years; white, 63 years), and baseline HbA1c was higher (South Asian, 65.8 mmol/mol; black,
69.3 mmol/mol; white, 64 mmol/mol) (Table 1).
Patterns of glucose-lowering treatment
Overall, 36.2% of individuals remained on noninsulin monotherapy for the entire study
period, 26.0% intensified from noninsulin monotherapy to noninsulin combination therapy,
and 6.8% intensified from monotherapy to combination therapy to insulin therapy. Individu-
als with treatment patterns differing from guidelines included those who initiated with nonin-
sulin combination therapy (3.5%) or insulin therapy (1.2%), those who intensified from
noninsulin monotherapy directly to insulin (1.8%), and those who initiated with combination
therapy and intensified to insulin (1.0%); 23.8% of the study population did not initiate any
glucose-lowering treatment during the study period (Fig 2).
The ordering of glucose-lowering drug classes was comparable between ethnic groups at
initiation but diverged in later stages. In all ethnic groups, the most popular first-line treatment
was metformin (82%), the most popular second-line treatment was sulfonylureas (50%), and
the most popular third-line treatments were newer-generation agents (34%). The choice for
the fourth and fifth additional agent differed substantially by ethnic group; whereas South
Asian and black groups were most likely to receive an additional newer-generation agent in
both stages, white groups were more likely to receive insulin (Fig 3).
Time to treatment initiation and intensification
Median time to initiation of noninsulin monotherapy was 3.2 months. Median time to intensi-
fication to noninsulin combination therapy was 28.5 months (2.4 years), and median time to
intensification to insulin therapy was 45 months (3.8 years).
After adjusting for age, sex, deprivation, comorbidities, baseline HbA1c, BMI and smoking
status, count of consultations and medications, calendar year, and clustering by practice, time
to initiation was 21% faster in South Asian groups (95% CI 8%–36%, p< 0.001) and 29% faster
in black groups relative to white (95% CI 5%–59%, p = 0.017). In contrast, time to intensifica-
tion with noninsulin combination therapy was significantly slower for both nonwhite ethnic
groups relative to white (South Asian HR 0.80, 95% CI 0.74–0.87, p< 0.001; black HR 0.79,
95% CI 0.70–0.90, p< 0.001). Ethnic differences widened further for intensification to insulin
therapy, with South Asian groups taking twice as long to intensify as white groups (HR 0.49,
95% CI 0.41–0.58, p< 0.001) and black groups taking 31% longer to intensify (HR 0.69, 95%
CI 0.53–0.89, p< 0.001) (Table 2, S3 Fig).
In all treatment stages, nonwhite ethnic groups had fewer HbA1c measurements than white
groups after adjusting for all confounders (Table 2).
Ethnic differences in therapeutic inertia
From the total study population, 79,720 individuals with at least 12 months of follow-up fol-
lowing their first raised HbA1c value of>7.5% (58 mmol/mol) were included in the analysis
of treatment inertia (S4 Fig).
Of all individuals who were treatment naive at diagnosis, 18% experienced therapeutic iner-
tia when initiating treatment with noninsulin monotherapy. After accounting for all
PLOS MEDICINE Ethnic differences in initiation and intensification of T2DM treatment
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Table 1. Baseline characteristics stratified by ethnic group.
Baseline characteristics White SA Black
N 150,754 8,139 3,345
Years of follow-up (mean, SD) 6.3 (4.6) 5.9 (4.7) 5.1 (4.4)
Age at diagnosis (mean, SD) 63.4 (13.2) 53 (12.9) 55.8 (13)
Gender, male, n (%) 82,619 (54.8) 4,411 (54.2) 1,679 (50.2)
Deprivation quintile
1 (least deprived), n (%) 27,606 (18.3) 1,030 (12.7) 191 (5.7)
2, n (%) 30,092 (20) 1,321 (16.2) 306 (9.1)
3, n (%) 33,318 (22.1) 1,721 (21.1) 717 (21.4)
4, n (%) 28,989 (19.2) 1,803 (22.2) 929 (27.8)
5 (most deprived), n (%) 30,749 (20.4) 2,264 (27.8) 1,202 (35.9)
Smoking status
Never smoker, n (%) 51,565 (34.2) 4,619 (56.8) 1,721 (51.4)
Current smoker, n (%) 23,503 (15.6) 843 (10.4) 342 (10.2)
Ex-smoker, n (%) 47,629 (31.6) 828 (10.2) 488 (14.6)
Missing, n (%) 28,057 (18.6) 1,849 (22.7) 794 (23.7)
BMI
BMI at diagnosis, kg/m2 (mean, SD) 31.7 (6.1) 29.2 (5.2) 31.3 (5.9)
Underweight (<20, <18.5 for SA) 1,447 (1) 23 (.3) 24 (.7)
Normal weight (20–25, 18.4–23 for SA) 13,560 (9) 532 (6.6) 309 (9.2)
Overweight (25–30, 23.5–27.5 for SA) 39,826 (26.4) 2,251 (27.8) 917 (27.4)
Obese (>30, >27.5 for SA) 71,664 (47.5) 4,013 (49.5) 1,521 (45.5)
Missing 24,257 (16.1) 1,287 (15.9) 574 (17.2)
HbA1c
HbA1c at diagnosis % (mean, SD) 8 (2.1) 8.2 (2.1) 8.5 (2.4)
HbA1c at diagnosis, IFCC (mean, SD) 63.6 (23.2) 65.8 (22.7) 69.3 (26.7)
�7.5%, n (%) 64,642 (42.9) 3,285 (40.4) 1,284 (38.4)
7.5%–7.9%, n (%) 11,191 (7.4) 767 (9.4) 305 (9.1)
8.0%–8.9%, n (%) 13,291 (8.8) 847 (10.4) 327 (9.8)
�9.0%, n (%) 29,594 (19.6) 1,692 (20.8) 849 (25.4)
Missing, n (%) 32,036 (21.3) 1,548 (19) 580 (17.3)
Blood pressure
SBP at diagnosis (mean, SD) 140.3 (18.8) 133.2 (17.6) 137.5 (18.5)
DBP at diagnosis (mean, SD) 80.9 (10.9) 80.8 (10.5) 82.5 (10.8)
<140/90, n (%) 27,185 (19) 1,131 (14.8) 671 (21.1)
<150/90, n (%) 20,424 (14.3) 737 (9.6) 471 (14.8)
<130/80, n (%) 76,154 (53.2) 3,384 (44.3) 1,683 (52.9)
Missing, n (%) 7,564 (5) 500 (6.1) 166 (5)
Comorbidities and medications
Any macrovascular, n (%) 21,669 (14.4) 685 (8.4) 198 (5.9)
Any microvascular, n (%) 4,685 (3.1) 202 (2.5) 96 (2.9)
Depression, n (%) 34,246 (22.7) 1973 (24.2) 721 (21.6)
On antihypertensive at diagnosis, n (%) 43,427 (28.8) 1,428 (17.5) 555 (16.6)
On statin at diagnosis, n (%) 77,072 (51.1) 3,641 (44.7) 1,295 (38.7)
DM treatment initiation characteristics
Initiate <1 year before diagnosis, n (%) 10,654 (7.1) 691 (8.5) 282 (8.4)
Initiate in 12 months prior to diagnosis, n (%) 33,034 (21.9) 2,347 (28.8) 1,086 (32.5)
Initiate within 90 days of diagnosis, n (%) 27,804 (18.4) 1,609 (19.8) 704 (21)
(Continued)
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hypothesised confounders, no ethnic differences in therapeutic inertia were evident (South
Asian odds ratio [OR] 0.97, 95% CI 0.76–1.24, p = 0.796; black OR 0.94, 95% CI 0.69–1.28, p =
0.683).
Of all individuals on noninsulin monotherapy, 68% experienced therapeutic inertia when
intensifying to noninsulin combination therapy. Both South Asian and black groups experi-
enced greater therapeutic inertia than white groups at this stage (South Asian OR 1.45, 95% CI
1.23–1.70, p< 0.001; black OR 1.43, 95% CI 1.09–1.87, p = 0.010).
Over 93% of all individuals on noninsulin combination therapy experienced therapeutic
inertia when intensifying to insulin therapy. At this stage, ethnic minority groups were sub-
stantially more likely to experience therapeutic inertia than white groups (South Asian OR
2.68, 95% CI 1.89–3.80, p< 0.001; black OR 1.82, 95% CI 1.13–2.92, p = 0.013) (Table 3).
Secondary analyses
As in the primary analysis, no ethnic differences in the odds of experiencing therapeutic inertia
were evident for initiation of noninsulin monotherapy when using 6.5% (48 mmol/mol) as the
cutoff for raised HbA1c instead of>7.5% (58 mmol/mol) (South Asian OR 0.86, 95% CI 0.67–
1.12, p = 0.274; black OR 0.86, 95% CI 0.60–1.23, p = 405) (S5 Table). Furthermore, the ethnic
Table 1. (Continued)
Baseline characteristics White SA Black
Initiate >90 days after diagnosis, n (%) 45,187 (30) 2,293 (28.2) 666 (19.9)
Noninitiators of DM treatment, n (%) 34,075 (22.6) 1,199 (14.7) 607 (18.1)
Baseline measures of HbA1c, BP, and CVD risk defined as value closest to diagnosis date in the 12 months prior or 3 months after.
Abbreviations: BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; HbA1c, glycated
haemoglobin; IFCC, International Federation of Clinical Chemistry; SA, South Asian; SBP, systolic blood pressure
https://doi.org/10.1371/journal.pmed.1003106.t001
Fig 2. Diabetes therapy intensification sequence from diagnosis to end of follow-up by ethnic group. NIAD, noninsulin antidiabetic drug.
https://doi.org/10.1371/journal.pmed.1003106.g002
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breakdown of individuals eligible for inclusion in the analysis of therapeutic inertia was com-
parable to the ethnic breakdown of individuals excluded due to insufficient follow-up after
their initial raised HbA1c measure (S6 Table, full models for all analyses are in S7 Table).
Discussion
To our knowledge, this is the first UK-based study to examine the extent to which the appro-
priate and timely prescribing of diabetes treatment among individuals with type 2 diabetes dif-
fers by ethnic group. We report two main findings: Firstly, despite initiating noninsulin
monotherapy more quickly after diagnosis than white groups, South Asian and black groups
were more likely to experience delays when intensifying to noninsulin combination therapy
and insulin therapy. Secondly, upon having uncontrolled HbA1c identified by the healthcare
provider, South Asian and black groups were more likely to experience therapeutic inertia
when intensifying to combination and insulin therapy.
Although several previous studies have quantified timeliness of initiation and intensifica-
tion of antidiabetic medication in UK and international populations, ours is the first to identify
differences by ethnic group. Similarly, although the literature describing ethnic differences in
diabetic outcomes is extensive, we propose a mechanism via which these inequalities might
occur—namely, via delayed intensification of treatment and therapeutic inertia following the
identification of uncontrolled risk. Recognising this mechanism enables us to identify several
priority target areas for reducing ethnic inequalities in the long-term management of diabetes
in primary care settings.
Our data suggest that excessive delays in treatment intensification in ethnic minority popu-
lations may result from poorer monitoring of risk factors in these populations; in our study,
both South Asian and black groups received fewer HbA1c measurements than white groups
prior to intensification with both noninsulin combination therapy and insulin.
Fig 3. Drug classes by intensification stage and ethnic group. DPP4i, dipeptidyl peptidase-4 inhibitor; GLP-1, glucagon-like peptide-1; SA, South Asian; TZD,
thiazolidinedione.
https://doi.org/10.1371/journal.pmed.1003106.g003
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A recent systematic review of 53 studies worldwide has highlighted the widespread problem
of therapeutic inertia in diabetes—with delays common across all stages of treatment initiation
and intensification, though most pronounced around the time of intensification to insulin
[22,26]. Correspondingly, we found that 67% of those intensifying to noninsulin combination
therapy and 93% of those intensifying to insulin therapy experienced treatment inertia.
Strengths and weaknesses of this study
The strengths and limitations of routine EHRs for the purposes of diabetes research have been
comprehensively outlined in a 2017 review [27]. This study benefitted from a large sample size
drawn from a UK primary care database of over 15 million individuals, known to be represen-
tative of the UK population with respect to age, sex, and ethnicity [17]. This allowed for well-
powered comparisons between the three main ethnic groups in the UK. The sample size of this
study was significantly larger than those used in other recent UK and European studies; our
study included over 160,000 individuals, compared with 2,500 to 24,000 reported elsewhere
[23,24,28].
Table 2. Time to antidiabetic treatment initiation and intensification.
Initiation and intensification
characteristics
Initiation of noninsulin monotherapy Intensification to noninsulin
combination therapy
Intensification to insulin therapy
N eligible to initiate/intensify 146,693 113,518 60,108
White South Asian Black White South Asian Black White South Asian Black
N eligible to initiate/intensify 136,540 7,247 2,906 105,025 6,224 2,269 55,872 3,097 1,139
Percent who initiate/intensify at any
time
98.9% 99.4% 97.8% 46.2% 42.8% 39.0% 20.9% 14.1% 16.2%
Duration of diabetes at start of follow-
up period (years, mean, SD)
0 0 0 1.00
(1.99)
0.72 (1.63) 0.54 (1.47) 2.97
(3.05)
2.90 (3.05) 2.30 (2.92)
Time to treatment initiation/
intensification
Months to initiation/intensification
(mean, SD)
6.2
(33.5)
2.3 (17.4) 1.2 (15.4) 29.6
(45.1)
29.3 (43.6) 26.7 (42.6) 45.5
(59.8)
47.5 (64.5) 42.7 (60.6)
Relative risk versus white (HR, 95% CI,
p-value)
1 1.21 (1.08–
1.36) <0.001
1.29 (1.05–
1.59) 0.017
1 0.80 (0.74–
0.87) <0.001
0.79 (0.70–
0.90) <0.001
1 0.49 (0.41–
0.58) <0.001
0.69 (0.53–
0.89) 0.004
Between-treatment characteristics
Mean HbA1c at diagnosis/start of
follow-up period (%)
8 (2.1) 8.1 (2) 8.4 (2.4) 8.6 (1.9) 8.5 (1.9) 8.9 (2.3) 8.9 (1.8) 9 (1.9) 9.6 (2.3)
Mean HbA1c closest to date of
initiation/intensification (%)
8.6 (2) 8.6 (1.9) 8.9 (2.3) 8.8 (1.7) 8.9 (1.8) 9.3 (2.1) 10 (1.9) 10.1 (1.9) 11 (2.5)
Number of HbA1c measurements
between treatment stages (mean, SD)
1.5 (2.9) 1.1 (2.3) 0.8 (2.1) 1.7 (3.1) 1.2 (2.3) .9 (2.1) 1.4 (2.5) 1 (1.9) 0.8 (2.1)
HbA1c count (RR, 95% CI, p-value) 1 0.94 (0.90–
0.98) 0.002
0.90 (0.83–
0.98) 0.017
1 0.78 (0.70–
0.85) <0.001
0.72 (0.60–
0.87) <0.001
1 0.74 (0.63–
0.87) <0.001
0.64 (0.50–
0.82) <0.001
Number of consultations between
treatment stages (mean, SD)
12
(27.6)
9 (20.7) 6.9 (19) 14.8
(29.9)
10 (21.4) 8 (20.6) 11.3
(23.5)
7.9 (17.8) 6.4 (16.4)
Consultation (RR, 95% CI, p-value) 1 0.98 (0.94–
1.02) 0.329
0.98 (0.93–
1.04) 0.541
1 0.89 (0.78–
1.01) 0.071
0.82 (0.66–
1.01) 0.062
1 0.63 (0.52–
0.76) <0.001
0.77 (0.59–
1.01) 0.061
Population eligible for initiation excludes those on any diabetes drug in 90 days prior to diagnosis. All models adjusted for age, sex, deprivation, year of diagnosis,
HbA1c, BMI, micro- and macro vascular comorbidities, depression, consultation count, smoking status and medication count at start of follow-up period, and
clustering by practice. Models for intensification to combination therapy and insulin additionally account for time since diagnosis. Mean HbA1c and BMI taken as the
latest in the 6 months prior to diagnosis (for model 1), initiation (for model 2), and intensification 1 (for model 3).
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin; RR, rate ratio
https://doi.org/10.1371/journal.pmed.1003106.t002
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Furthermore, the crude time to intensification with insulin reported in our study (3.8
years) matched those of the UK-based cohort studies, which reported median times to insulin
initiation between 3.2 and 4.9 years, indicating consistency of data quality and representative-
ness of the target population [24,28].
Thanks to the quality and outcomes framework, recent improvements in the completeness
and quality of both diabetes and ethnicity data have facilitated robust examinations of ethnic
differences in the management of type 2 diabetes in primary care settings [19,29]. Diagnoses of
T2DM were ascertained using a validated algorithm designed to minimise miscoding and mis-
classification of diabetes type, reducing the likelihood that individuals with type 1 diabetes or
other forms of diabetes were included in our study population [18]. Restriction of the study
sample to individuals with at least 12 months of continuous registration prior to their initial
diagnosis of T2DM ensured that diagnoses were truly incident and that a sufficient look-back
period to capture key baseline covariates was present.
By restricting the analyses to white, South Asian, and black African/Caribbean groups, we
were able to make clinically relevant comparisons between well-defined populations with dis-
tinct biological, sociocultural, and demographic characteristics, which can be meaningfully
characterised as ethnicity [30]. Linkage to area-level deprivation data enabled us to separate
the influences of ethnicity and deprivation, which are often conflated when examining health
disparities.
General practice characteristics, such as size and participation in local enhanced service
schemes, have been found to play a large role in observed variations in the quality of diabetes
care [31]. By accounting for the clustering of individuals within general practices, we were able
to appropriately account for the influence of practice-level factors on ethnic disparities.
Several limitations may have influenced our findings: Firstly, as EHRs are primarily used
for patient care rather than research, data quality and completeness can vary significantly
depending on the time period, disease area, and indicator of interest. These issues were
Table 3. Ethnic differences in therapeutic inertia (failure to intensify treatment within 12 months of HbA1c>7.5%).
Treatment stage Ethic
group
N with any HbA1c >7.5%
and 12 months’ follow-up
Percent experiencing treatment
inertia at 12 months, % (n)
Months between first HbA1c >7.5%
and intensification/end f-up, mean
(SD)
Odds of
treatment
inertia
Initiation of noninsulin
monotherapy
White 34,546 18.4 (6,354) 6.9 (13.8) 1
South
Asian
1,683 16.2 (273) 6.3 (13) 0.97 (0.76–1.24),
0.796
Black 560 17.5 (98) 6.1 (13.2) 0.94 (0.69–1.28),
0.683
Intensification to noninsulin
combination therapy
White 54,307 67.1 (36,431) 29.2 (30) 1
South
Asian
3,076 69.4 (2,135) 29.8 (28.9) 1.45 (1.23–1.70),
<0.001
Black 1,029 68.7 (707) 31 (31.4) 1.43 (1.09–1.87),
0.010
Intensification to insulin
therapy
White 36,480 93 (33,920) 54.8 (38.7) 1
South
Asian
2,061 96.2 (1982) 61.3 (43.1) 2.68 (1.89–3.80),
<0.001
Black 702 94.4 (663) 57.8 (42) 1.82 (1.13–2.92),
0.013
Regression model adjusts for age, gender, deprivation, HbA1c value, BMI value, smoking status, macro- and microvascular comorbidities, and depression at start of
follow-up, number of consultations, and medications at the start of each follow-up period, calendar year at follow-up start, and clustering by practice. Models for
intensification to combination therapy and insulin additionally account for time since diagnosis.
Abbreviations: BMI, body mass index; HbA1c, glycated haemoglobin
https://doi.org/10.1371/journal.pmed.1003106.t003
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mitigated by using data on a chronic disease condition managed predominantly in primary
care settings [32,33] and by adjusting for calendar time in the analysis to account for secular
trends in prescribing guidelines and treatment availability.
Secondly, the length of follow-up may have been insufficient to adequately characterise
individuals intensifying with insulin therapy. Although 26.5% of the study population intensi-
fied from noninsulin monotherapy to noninsulin combination therapy during the follow-up
period, only 5.8% of the population underwent all three intensification stages.
Furthermore, our definition of therapeutic inertia may have been too crude when looking at
intensification to insulin therapy because individuals may have switched between various non-
insulin combinations for some time before up-titrating with insulin therapy. As shown in our
descriptive analysis, South Asian and black groups most commonly added noninsulin therapies
as their fourth- and fifth-line treatments, whereas white groups most frequently added insulin.
Although the CPRD captures prescriptions made by the general practitioner, it does not
hold any information on dispensing data; thus, we cannot know for certain whether prescrip-
tions were filled or taken by the individual. Finally, we were unable to explore ethnic differ-
ences in rates of nonattendance to planned appointments, which may be related to ethnic
differences in adherence to recommended therapeutic regimes and compliance with diabetes
management plans.
Implications for clinicians and policymakers
The findings of this study highlight clear ethnic disparities in the long-term therapeutic man-
agement of type 2 diabetes, which likely contribute, at least in part, to the worse outcomes seen
in ethnic minority populations in the UK. Given that baseline HbA1c prior to treatment initia-
tion was higher in the ethnic minority than the white groups, our finding of faster initiation of
noninsulin monotherapy in nonwhite groups is commensurate with the more advanced dis-
ease at diagnosis in the former groups. It may also reflect a preference for initial pharmacologi-
cal (as opposed to lifestyle) interventions in ethnic minority groups, possibly indicating greater
awareness of the disproportionate risk of major vascular outcomes in South Asian and black
populations. Correspondingly, our previous study examining ethnic differences in manage-
ment of type 2 diabetes around the time of diagnosis found that South Asian and black groups
were offered nonpharmacological interventions (structured diabetes management and risk
assessments) more quickly than white groups [34].
Reasons for treatment delays can stem from the healthcare system, the practitioner, and the
patient. In the UK, these barriers include competing demands on practitioner time, financial
constraints of the NHS (particularly in relation to the costs of newer medications), patient
adherence, and concerns over side effects [35]. Intensification to insulin is particularly chal-
lenging because of the complexity of administration, the level of instruction required, and
patient concerns around the use of injectable treatments [36]. Such challenges may be further
exacerbated by cultural and language barriers on both the patient [37,38] and provider side
[39], potentially explaining excessive delays in treatment intensification among ethnic minor-
ity groups. Ethnic differences in health beliefs and attitudes toward medication may also play a
role in therapeutic inertia. A recent study from the United States found that statin undertreat-
ment among African American groups was partially explained by lower levels of trust in
healthcare practitioners and lower perceived safety of statins in the African American popula-
tion compared with the white population [40]. Similarly, a UK survey of the Bangladeshi popu-
lation found that refusal of insulin treatment was associated with fear of premature death, fear
of weight gain, loss of independence, and lack of perceived improvements to quality of life
[38].
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Considering the wider spectrum of cardiometabolic disease, therapeutic inertia remains a
substantial problem in the management of blood pressure and lipids. As with diabetes, causes
for inertia in other disease areas are multifactorial, stemming from patient and provider,
healthcare system, and policy factors. In addition to the important role of patient beliefs and
understanding of health conditions and treatment options, other studies have highlighted the
importance of education around clinical guidelines for both clinicians and patients, the use of
multidisciplinary clinical teams, and the importance of quality improvement initiatives such as
pay-for-performance schemes [41,42].
A final consideration is that treatment inertia may be appropriate for certain populations.
As treatment decisions are increasingly made jointly between individuals and their care pro-
viders, purposeful therapeutic inertia may reflect shared concerns around frailty, treatment
burden, and competing health-related priorities [43,44]. Risk of hypoglycaemia increases sig-
nificantly with age and may be a key consideration in delaying treatment intensification in
older age groups [45]. It is likely that some of the delays evident in our study population may
be the result of individualised target setting to avoid overtreatment, particularly around the
time of insulin intensification. However, even after accounting for burden of comorbidities,
age, HbA1c, BMI, and medications, we found compelling evidence that ethnic minority groups
nevertheless experience treatment inertia to a far greater degree than the white population.
Unanswered questions and future research
The first question arising from this work is to determine the relationship between prescribing
patterns, long-term glycaemic control, and ethnic differences in micro- and macrovascular
outcomes. Secondly, though difficult to quantify in EHRs, determining ethnic differences in
adherence to diabetes treatment may shed light on how best to support specific population
groups in maintaining good glycaemic control over the longer term. Thirdly, examining ethnic
differences in the comparative effectiveness of different treatment regimes with respect to car-
diovascular outcomes will be key to developing tailored treatment guidelines for multiethnic
populations. Replicating and extending trials such as these to determine whether the risks and
benefits of these treatments manifest differently between ethnic groups in real-world settings
will form essential next steps toward the personalisation of care in populations with type 2
diabetes.
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